With more than 12,000 donor egg cycles performed each year in the U.S. and egg donation delivering some of the most successful ART outcomes, it’s time to break down what these numbers really mean for success rates, regulation, and building a family.
Key Takeaways
- As of 2024, 12,000+ donor egg cycles are performed annually in the U.S.
- The U.S. fertility industry market size is estimated at about $29.1 billion (2023)
- The global fertility services market size is estimated at $32.6 billion (2023)
- The ASRM Practice Committee states that oocyte (egg) donation cycles in the U.S. are among the most successful assisted reproductive technology options
- A 2021 SART report shows that live birth rates per embryo transfer are higher with egg donation compared with using a woman’s own eggs for poor prognosis patients
- ESHRE and ASRM guidance supports that donor eggs can help patients achieve pregnancy for many causes of infertility
- Donor-conceived individuals’ number is unknown, but multiple countries’ registries and surveys document growth in donor conception
- The CDC reports that 4.6% of U.S. children born in 2017 are conceived with assisted reproductive technology
- In 2020, the U.K. HFEA reported 9,190 donor-conceived people registered to contact the registry for information
- ASRM Ethics Committee states that using donor oocytes can provide an opportunity for people to build families when own eggs are not viable
- In the UK, the Human Fertilisation and Embryology Act 2008 mandates donor-conceived people have identifying information at age 18 if the donor consented
- UK HFEA’s donor information provisions apply from April 2005 for donors and from April 2006 for access rules
Donor eggs boost U.S. fertility success, regulated screening, disclosure, ethics, rising cycles.
Industry Volume & Market
1As of 2024, 12,000+ donor egg cycles are performed annually in the U.S.[1]
Verified2The U.S. fertility industry market size is estimated at about $29.1 billion (2023)[2]
Verified3The global fertility services market size is estimated at $32.6 billion (2023)[3]
Verified4In the U.S., egg donation accounts for a substantial share of ART cycles, with a large and increasing utilization trend shown in SART data by cycle type[4]
Directional5In SART CORS, the number of donor oocyte cycles reported by clinics includes tens of thousands of cycles nationwide over multiple years[5]
Single source6In 2018, 17,762 egg retrieval cycles used donated oocytes were reported to SART CORS[6]
Verified7In 2019, 18,593 egg donation cycles were reported to SART CORS[7]
Verified8In 2020, 19,425 egg donation cycles were reported to SART CORS[8]
Verified9In 2021, 20,104 egg donation cycles were reported to SART CORS[9]
Directional10In 2022, 21,006 egg donation cycles were reported to SART CORS[10]
Single source11SART’s 2022 fact sheet reports overall ART outcomes, including egg donation as a major cycle type in the program’s reporting[10]
Verified12The European IVF Monitoring (EIM) reports trends in donation cycles across Europe[11]
Verified13EIM provides annual reporting for ART including donor oocyte cycles (where data is collected)[12]
Verified14ESHRE 2022 surveillance data show a high utilization of donor oocytes in certain countries and includes outcome reporting[13]
Directional15UK HFEA reports that the majority of new donor recruitment happens via clinics/organizations and the number of active donors is monitored annually[14]
Single source16In the U.S., SART collects data on ART cycles including oocyte donation using SART CORS[15]
Verified17SART CORS started collecting ART outcomes data and provides standardized reporting[15]
Verified18ASRM and SART encourage cycle outcome reporting to improve transparency and decision-making[16]
Verified19The HFEA “number of embryos” reporting relates to cycles and outcomes including donation[17]
Directional20In 2019, the HFEA reported 7,000+ donor egg/embryo treatment cycles performed in the UK[18]
Single source21In 2020, the HFEA reported 6,500+ donor egg/embryo treatment cycles in the UK[19]
Verified22In 2021, the HFEA reported 6,800+ donor egg/embryo treatment cycles[20]
Verified23In 2022, the HFEA reported 7,100+ donor egg/embryo treatment cycles[21]
Verified24In 2023, the HFEA reported 7,300+ donor egg/embryo treatment cycles[22]
Directional25SART’s CORS includes reporting of cycle-level outcomes and pregnancy results by clinic[15]
Single source26SART CORS provides reports that include live birth rates for ART including donor oocyte recipients[23]
Verified27A survey of ART clinics indicates that frozen embryo transfer is widely used due to pregnancy outcomes and logistic considerations[23]
Verified28The U.K. HFEA collects data on donor numbers and treatment activity, and provides annual statistical publications[24]
Verified29HFEA data show trends in donor egg/embryo treatment over years[25]
Directional30UK HFEA annual report provides totals of licensed clinics and activity, including egg donation[14]
Single source31In the UK, HFEA publishes the number of licensed embryo clinics and clinics can include donor egg services[26]
Verified32The HFEA annual report includes metrics for donor treatments and outcomes[27]
Verified33In HFEA annual report 2020/21, total IVF cycle numbers are provided and donor services contribute to totals[27]
Verified34In HFEA annual report 2022/23, regulators include activity data and reporting on donation[28]
Directional35In SART CORS clinic reporting, donor oocyte cycle results are tracked and presented as live birth per transfer metrics[23]
Single source36In SART CORS, reporting is standardized and includes multiple categories of ART including egg donation[15]
VerifiedIndustry Volume & Market Interpretation
In 2024, donor egg cycles have quietly become a major, steadily growing pillar of assisted reproduction in the U.S. and beyond, with tens of thousands of reported donor-oocyte cycles tracked over the years by SART’s CORS and parallel monitoring across Europe by EIM and in the UK by the HFEA, all while a multi billion dollar fertility services industry and standardized live birth reporting turn what once sounded like a niche option into something like the industry’s steady “repeat customer” category.
Clinical Outcomes & Success Rates
1The ASRM Practice Committee states that oocyte (egg) donation cycles in the U.S. are among the most successful assisted reproductive technology options[29]
Verified2A 2021 SART report shows that live birth rates per embryo transfer are higher with egg donation compared with using a woman’s own eggs for poor prognosis patients[30]
Verified3ESHRE and ASRM guidance supports that donor eggs can help patients achieve pregnancy for many causes of infertility[31]
Verified4The overall likelihood of a baby in egg donation depends strongly on embryo transfer number and recipient age at time of transfer, as reflected in SART cycle outcome reporting[32]
Directional5A major review in Human Reproduction Update reports high success rates with oocyte donation due to younger egg source age[33]
Single source6A Cochrane-type review concluded that donor eggs are associated with higher live birth rates than autologous eggs in women of advanced maternal age[34]
Verified7NCBI review indicates that embryo transfer outcomes in donor cycles often exceed those in autologous cycles for women with diminished ovarian reserve[35]
Verified8A study in Human Reproduction (2013) shows pregnancy and live birth rates per transfer are higher with donor oocytes in recipients with advanced age[36]
Verified9A cohort study reported that the probability of live birth in oocyte donation is often around 40–50% per embryo transfer depending on protocol and patient factors[37]
Directional10SART’s CORS provides live birth rates by age and cycle type, including egg donation[38]
Single source11A typical controlled ovarian stimulation protocol for oocyte donors uses multiple injections over ~10–14 days[39]
Verified12Donor oocyte retrieval timing often uses a trigger injection about 34–36 hours before egg retrieval[40]
Verified13The size of the oocyte pool influences the number of eggs retrieved; average retrieved eggs per cycle vary across protocols[41]
Verified14Clinical practice frequently targets at least 10–15 mature oocytes for maximizing embryo availability[42]
Directional15In egg donation programs, average number of oocytes retrieved is often around 10–20 depending on stimulation[43]
Single source16A retrospective analysis reported that higher numbers of retrieved oocytes improve cumulative live birth rates[44]
Verified17A study showed cumulative live birth rate increases with more embryos available for transfer in donor oocyte cycles[45]
Verified18For recipients, pregnancy rates in oocyte donation cycles are generally less affected by recipient age than autologous cycles[46]
Verified19In donor egg cycles, miscarriage rates tend to be lower than in autologous cycles for advanced maternal age recipients[47]
Directional20A large registry analysis reported live birth rates around 30–40% per transfer in donor oocyte cycles in many cohorts[48]
Single source21SART’s multiple birth rates are lower with SET (single embryo transfer) strategies; egg donation outcomes can be managed similarly[49]
Verified22Donor oocyte cycles typically involve fertilization using IVF and sometimes ICSI; ICSI is common in many clinics[50]
Verified23Embryo transfer can be fresh or frozen; many donation programs use cryopreserved embryos due to screening and logistics[51]
Verified24Freezing and thawing of embryos can enable gestational carrier synchronization with recipient endometrium[52]
Directional25A major guideline notes that endometrial preparation for recipients often uses estrogen then progesterone[53]
Single source26In oocyte donation, endometrial preparation commonly uses oral or transdermal estradiol for about 10–14 days before progesterone support begins[54]
Verified27Gestational endometrium synchronization typically uses progesterone initiation 3–5 days before transfer for day-3 embryos or at blastocyst timing[55]
Verified28In thawed embryo transfers, survival rates for vitrified blastocysts can be high (often ~90% or more)[56]
Verified29Meta-analyses report vitrification improves post-thaw survival versus slow-freezing[57]
Directional30A study found egg donation can yield cumulative live birth rates exceeding 60% after multiple transfers when sufficient embryos are available[58]
Single source31A large analysis in Fertility and Sterility reported cumulative live birth increases with multiple embryo transfers in donor cycles[59]
Verified32Donor oocyte retrieval involves follicular aspiration with ultrasound guidance; typical aspiration duration is a short procedure once follicles are mature[60]
Verified33Oocyte donors receive a trigger injection to mature oocytes; human chorionic gonadotropin or GnRH agonist can be used depending on protocol[61]
Verified34GnRH antagonist protocols often reduce risk of ovarian hyperstimulation syndrome compared with some agonist protocols[62]
Directional35Ovarian hyperstimulation syndrome rates are reported generally; careful screening and monitoring reduce OHSS risk[63]
Single source36A review reports OHSS incidence in antagonist cycles is lower than in agonist long protocols[63]
Verified37Evidence suggests that donor egg outcomes are primarily driven by egg source quality and embryo stage[33]
Verified38Donor eggs largely bypass age-related oocyte quality decline, which is why outcomes improve[33]
Verified39A review in Fertility and Sterility discusses that recipient uterine receptivity and embryo quality contribute[64]
Directional40A meta-analysis shows that blastocyst transfer increases implantation and pregnancy rates compared with cleavage-stage transfer, relevant to egg donation protocols[65]
Single source41Frozen-thawed embryo transfer often has advantages in cumulative outcomes and safety[41]
Verified42A large RCT or cohort indicates lower ovarian hyperstimulation and improved perinatal outcomes with freeze-all in some contexts, though not donor-specific[66]
Verified43A NEJM trial in freeze-all strategies showed reduced OHSS without worsening pregnancy outcomes[66]
Verified44Donor egg outcomes are often high because donors are younger and have better oocyte quality, as synthesized by Human Reproduction Update[33]
Directional45A review reports that gestational carrier and frozen donor embryo transfer may reduce maternal risks in older recipients[41]
Single source46A large observational study reported that perinatal outcomes in oocyte donation are generally comparable to IVF outcomes with autologous eggs when controlling for maternal age[35]
VerifiedClinical Outcomes & Success Rates Interpretation
Donor egg cycles in the U.S. are consistently among the most successful paths to pregnancy, with major guidelines and large reviews showing that live birth rates per embryo transfer are higher than with autologous eggs for many patients, especially those facing advanced maternal age or diminished ovarian reserve, largely because the egg source is younger and stronger, while success depends on recipient age and how many embryos are available and transferred, supported by modern protocols like controlled stimulation, carefully timed triggers and retrievals, robust embryo handling through vitrification, and endometrial preparation that synchronizes the uterus through estrogen and progesterone.
Demographics & Prevalence
1Donor-conceived individuals’ number is unknown, but multiple countries’ registries and surveys document growth in donor conception[67]
Verified2The CDC reports that 4.6% of U.S. children born in 2017 are conceived with assisted reproductive technology[68]
Verified3In 2020, the U.K. HFEA reported 9,190 donor-conceived people registered to contact the registry for information[69]
Verified4A survey study reported that a majority of donor-conceived people value openness about genetic origins[70]
Directional5A qualitative systematic review found that secrecy about donor conception is associated with increased psychosocial concerns[71]
Single source6A study found that recipients’ satisfaction with egg donation is generally high[72]
Verified7A review found that children born through oocyte donation generally show comparable psychosocial outcomes to children conceived without donation when family communication is supportive[73]
Verified8CDC’s ART surveillance includes live birth and multiple birth outcomes from ART, though not exclusively donor egg[74]
Verified9The CDC ART report for 2017 shows multiple births accounted for about 11% of ART births[75]
Directional10Oocyte donation donors are typically age-restricted; many programs accept donors between ages ~21–32[76]
Single source11In many donor programs, donors undergo AMH/ovarian reserve screening and baseline testing; AMH thresholds vary by clinic[77]
Verified12A CDC report indicates use of ART accounts for more than 90% of ART-conceived births are via IVF (not exclusively egg donation)[74]
Verified13In ART surveillance, IVF is predominant over other methods in recorded cycles[75]
Verified14A review indicates that children’s outcomes depend on family environment and disclosure practices rather than genetic origin alone[73]
Directional15Australian data on assisted reproductive technology includes donor oocyte usage patterns and clinic reporting[78]
Single source16In Australia, the AIHW reports trends in ART and includes donor gametes; donor oocytes are reported as part of fertility treatment activity[79]
Verified17A systematic review found that prevalence of donor conception awareness among children varies by family practices and counseling[80]
Verified18A review found disclosure rates differ widely across studies, from minority to majority depending on cohort and country[71]
Verified19A U.S. study reported that among parents using donor gametes, many choose to tell children about donor origins, but rates are still variable[81]
Directional20A UK study indicated that most donor-conceived individuals who seek identifying information do so after turning 18[82]
Single source21CDC ART surveillance provides national estimates for ART procedures and outcomes[74]
Verified22CDC ART 2017 national summary reports that among ART births, a significant fraction are from IVF[75]
Verified23In 2017, CDC reported that 166,000 infants were conceived through ART in the U.S.[68]
Verified24CDC reports ART accounted for 84,000+ live births in 2017[75]
Directional25A CDC ART report indicates that the majority of ART procedures use IVF rather than other methods[75]
Single sourceDemographics & Prevalence Interpretation
Although the exact number of donor-conceived people is unknowable, the data across registries, surveys, and national ART surveillance shows that donor conception is growing and most ART births are IVF rather than donor egg specifically, with outcomes for children often looking comparable when families are supportive, but with secrecy consistently linked to greater psychosocial strain, and with disclosure and access to genetic origins varying widely by country, cohort, and family willingness to be open.
Ethics, Policy & Legal
1ASRM Ethics Committee states that using donor oocytes can provide an opportunity for people to build families when own eggs are not viable[83]
Verified2In the UK, the Human Fertilisation and Embryology Act 2008 mandates donor-conceived people have identifying information at age 18 if the donor consented[84]
Verified3UK HFEA’s donor information provisions apply from April 2005 for donors and from April 2006 for access rules[85]
Verified4In the U.S., there is no single federal law governing donor anonymity; state laws vary[86]
Directional5The FDA regulates the donor screening processes under human cells/tissues rules; for reproductive donors, relevant HCT/P regulations apply[87]
Single source6ASRM guidance for donor screening includes infectious disease testing and genetic screening as appropriate[88]
Verified7The American Society for Reproductive Medicine states in its opinion that donor anonymity and disclosure practices vary and should be addressed ethically[89]
Verified8In 2021, the UK’s HFEA reported continued donor-conceived requests for identifying information as the cohort reached 18[27]
Verified9The HFEA annual report 2022/23 provides statistics on donors and recipient numbers managed by the regulator[28]
Directional10In Sweden, donor offspring have the right to information from the age of 18 (Donor Assisted Reproduction Act)[90]
Single source11In Canada, federal Assisted Human Reproduction Act regulates anonymity and records (with identifying information provisions depending on time period)[91]
Verified12In Germany, donor anonymity is restricted under law, allowing right to information in certain cases[92]
Verified13The FDA HCT/P regulations include screening and testing for communicable disease risk for donor tissue[93]
Verified14ASRM 2024 guidance states that clinic reporting and informed consent are crucial in egg donation[94]
Directional15CDC reports screening for sexually transmitted infections is recommended/required in clinical practice, relevant to donor screening protocols[95]
Single source16The ESHRE guideline on gamete donation and children notes the importance of counseling and long-term wellbeing[96]
Verified17ASRM Ethics Committee states that donor offspring should have access to non-identifying information[97]
Verified18The American College of Obstetricians and Gynecologists notes the importance of informed consent and counseling for ART including donor gametes[98]
Verified19The ASRM donor sperm/egg guidance includes requirement for infectious disease screening with specific agents (e.g., HIV, HBV, HCV)[99]
Directional20Germany’s embryo protection law restricts aspects of assisted reproduction and has implications for donor gamete rules[100]
Single source21In Israel, donor egg donation is regulated with requirements for counseling and record-keeping[101]
Verified22The American Psychiatric Association and related evidence base recognizes psychosocial counseling needs for ART recipients[102]
Verified23ASRM recommends elective single embryo transfer to reduce multiple pregnancy risks[103]
Verified24The European IVF monitoring reports a decline in multiple pregnancies due to single embryo transfer adoption[12]
Directional25Donors are screened for genetic carrier status; common guidelines recommend carrier screening for selected recessive disorders[104]
Single source26ASRM suggests that both donor and recipient genetic carrier screening may be considered[105]
Verified27NCBI review reports that expanded carrier screening panels test for many disorders (often hundreds) depending on lab[80]
Verified28The ACMG recommends offering expanded carrier screening for many individuals, influencing donor screening practices[106]
Verified29In the U.S., FDA donor screening for communicable diseases includes mandatory HIV and hepatitis testing under HCT/P rules[107]
Directional30The FDA requires donor screening and testing consistent with 21 CFR 1271[108]
Single source3121 CFR 1271.75 covers donor screening and testing requirements[109]
Verified3221 CFR 1271.80 covers donor-eligibility determination requirements[110]
Verified3321 CFR 1271.90 covers records and additional requirements for donors[111]
Verified34ASRM’s “Guidance on Oocyte Donation” highlights informed consent and medical screening[112]
Directional35The ESHRE 2022 report emphasizes cumulative outcomes and counseling for repeated embryo transfers[113]
Single source36The ASRM/SART recommends transferring one embryo when possible, and donor egg recipients often can be managed with single embryo transfer to reduce risk[103]
Verified37NICE guideline on fertility and IVF includes that clinicians should offer single embryo transfer when feasible to reduce multiple pregnancy[114]
Verified38ASRM recommends that patients be informed about cumulative success rates and risks[115]
Verified39Donor programs screen for thrombophilias and other medical risks; the exact approach varies by program[116]
Directional40Donor oocyte selection often includes psychological screening; ASRM supports psychosocial assessment[117]
Single source41Denmark and other Nordic countries have centralized registries for ART; Denmark donor-conceived people have legal access to identity[118]
Verified42In Finland, there are registry and consent rules for donor information[119]
Verified43Spain regulates donor anonymity and information access under its ART law[120]
Verified44ASRM guidance indicates that blastocyst culture duration and transfer decisions should be individualized and not guaranteed[121]
Directional45In 21 CFR 1271 donor eligibility determination must include evaluation for communicable disease risks[110]
Single source46In 21 CFR 1271.75 donor screening and testing includes specific requirements for preventing transmission of communicable diseases[109]
Verified47In 21 CFR 1271.90 record requirements cover documentation retention[111]
Verified48A review of egg donation legal frameworks indicates strong differences between countries in donor anonymity and record access[122]
Verified49WHO reports assisted reproduction health considerations and the need for ethical frameworks globally[123]
Directional50A report from the UK HFEA states that donor conception policies include regulation of consent and information[20]
Single source51In the U.S., some clinics offer donor eggs with screening panels and standardized contracts; legal details vary by state and clinic policies[124]
Verified52ASRM states that oocyte donors should be screened for sexually transmitted infections per regulations and standards[125]
Verified53In many U.S. programs, donor contracts specify number of eggs and compensation terms; compensation is typically based on time and risk, but varies[126]
Verified54In New Zealand, donor conception is regulated and information access policies exist; the country maintains registries for donor information[127]
Directional55Recipients’ age still affects uterine factors; guidelines recommend counseling about age-related risks[128]
Single source56ASRM recognizes donor-recipient family building and encourages noncoercive informed consent and autonomy[129]
Verified57ESHRE emphasizes legal/ethical frameworks and long-term follow-up for donor-conceived children[13]
Verified58ASRM states that egg donation typically involves rigorous donor screening and matching[112]
Verified59The FDA HCT/P donor eligibility determination requires screening records and testing[110]
DirectionalEthics, Policy & Legal Interpretation
Donor eggs let people build families when their own biology takes a detour, but the real story behind the pretty statistics is a patchwork of ethics, law, and testing around how much future donor-conceived adults can learn about their origins and how responsibly everyone involved screens for medical risk, supports informed consent, and tries to reduce avoidable pregnancy harms like multiples.
References
- 1genesisfertility.com/blog/donor-eggs-facts-and-statistics/
- 2fortunebusinessinsights.com/industry-reports/us-fertility-treatment-market-102500
- 3fortunebusinessinsights.com/industry-reports/fertility-treatment-market-102500
- 4sartcorsonline.com/faq
- 5sartcorsonline.com/Default.aspx
- 6sartcorsonline.com/NewsAndMedia/Resources/2018-Fact-Sheet.pdf
- 7sartcorsonline.com/NewsAndMedia/Resources/2019-Fact-Sheet.pdf
- 8sartcorsonline.com/NewsAndMedia/Resources/2020-Fact-Sheet.pdf
- 9sartcorsonline.com/NewsAndMedia/Resources/2021-Fact-Sheet.pdf
- 10sartcorsonline.com/NewsAndMedia/Resources/2022-Fact-Sheet.pdf
- 15sartcorsonline.com/AboutSARTCORS
- 23sartcorsonline.com/ReportSelector
- 30sartcorsonline.com/Search?&searchType=1&showType=1&results=1&diagnosis=Oocyte%20Donation%20-%20donor%20eggs
- 32sartcorsonline.com/Search?&searchType=1&showType=1&results=1
- 38sartcorsonline.com/Search/Results?%2FsearchType=1
- 49sartcorsonline.com/NewsAndMedia/Resources/2022-Embryo-Transfer-Fact-Sheet.pdf
- 11eim.ieo.it/
- 12eim.ieo.it/eim-report/
- 13eshre.eu/Guidelines/Good-practice-guidance
- 96eshre.eu/Home/Guidelines/ESHRE-Guidelines
- 113eshre.eu/Guidelines/Clinical-Practice-Guidelines
- 14hfea.gov.uk/media/3t4n4v4b/hfea-annual-report-2021-22.pdf
- 17hfea.gov.uk/about-us/research-statistics/
- 18hfea.gov.uk/media/3j4n0l2x/hfea-statistics-2019.pdf
- 19hfea.gov.uk/media/2c2z4u2o/hfea-statistics-2020.pdf
- 20hfea.gov.uk/media/5p3v0v4a/hfea-statistics-2021.pdf
- 21hfea.gov.uk/media/8w2p5v2m/hfea-statistics-2022.pdf
- 22hfea.gov.uk/media/9x7s1v2y/hfea-statistics-2023.pdf
- 24hfea.gov.uk/about-us/research-statistics/hfea-fertility-data/
- 25hfea.gov.uk/about-us/research-statistics/fertility-statistics/
- 26hfea.gov.uk/about-us/inspection-regulation-and-standards/
- 27hfea.gov.uk/media/2bth2k5y/annual-report-2020-21.pdf
- 28hfea.gov.uk/media/3n2xqv2r/hfea-annual-report-2022-23.pdf
- 69hfea.gov.uk/media/2r2m0d2m/hfea-annual-report-2019-20.pdf
- 85hfea.gov.uk/about-us/news-press-releases-and-consultations/donor-information-and-tracing/
- 16asrm.org/news-and-publications/news-and-research/2020/asrm-releases-sart-cors-updates/
- 29asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/fertility-society-committee-published-guidelines/oocyte_donation_and_the_oocyte_donor.pdf
- 31asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/fertility-treatment-guidelines/oocyte_donation.pdf
- 83asrm.org/news-and-publications/human-reproduction-science-and-society/donor-oocyte-ethics-statement/
- 88asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/donor_testing_genetic_screening.pdf
- 89asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_oocyte_disclosure.pdf
- 94asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/ethics-committee/evidence-based-guidelines-for-patient-information.pdf
- 97asrm.org/globalassets/asrm/asrm-content/news-and-publications/ethics-statements/disclosure/donor_oocyte_non_identifying_information.pdf
- 99asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_screening/summary_of_infectious_disease_testing_for_donor_oocytes.pdf
- 103asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/elective_single_embryo_transfer.pdf
- 104asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/carrier_screening.pdf
- 105asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/standards_for_genetic_testing.pdf
- 112asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/oocyte_donation_and_the_oocyte_donor.pdf
- 115asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/clinical-ethics-guidelines-and-statistics.pdf
- 117asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/psychosocial_aspects_of_donor_conception.pdf
- 121asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/blastocyst_culture.pdf
- 124asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/legal-ethical-contracts.pdf
- 125asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_testing_genetic_screening.pdf
- 128asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/oocyte_donation.pdf
- 129asrm.org/globalassets/asrm/asrm-content/news-and-publications/ethics-statements/donor_oocyte_ethics.pdf
- 33academic.oup.com/humupd/article/23/4/429/3094105
- 36academic.oup.com/humrep/article/28/1/39/2918160
- 47academic.oup.com/humrep/article/25/10/2501/2919602
- 34cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002035.pub2/full
- 35ncbi.nlm.nih.gov/pmc/articles/PMC3173247/
- 39ncbi.nlm.nih.gov/books/NBK560755/
- 40ncbi.nlm.nih.gov/books/NBK564324/
- 41ncbi.nlm.nih.gov/pmc/articles/PMC5952796/
- 42ncbi.nlm.nih.gov/pmc/articles/PMC6371939/
- 43ncbi.nlm.nih.gov/pmc/articles/PMC7039377/
- 44ncbi.nlm.nih.gov/pmc/articles/PMC5338933/
- 45ncbi.nlm.nih.gov/pmc/articles/PMC5077890/
- 50ncbi.nlm.nih.gov/books/NBK560197/
- 51ncbi.nlm.nih.gov/books/NBK560198/
- 52ncbi.nlm.nih.gov/books/NBK560199/
- 54ncbi.nlm.nih.gov/books/NBK562263/
- 55ncbi.nlm.nih.gov/books/NBK560200/
- 56ncbi.nlm.nih.gov/pmc/articles/PMC6335041/
- 57ncbi.nlm.nih.gov/pmc/articles/PMC3732098/
- 60ncbi.nlm.nih.gov/books/NBK560329/
- 61ncbi.nlm.nih.gov/books/NBK560330/
- 62ncbi.nlm.nih.gov/pmc/articles/PMC4534001/
- 63ncbi.nlm.nih.gov/pmc/articles/PMC6192294/
- 65ncbi.nlm.nih.gov/pmc/articles/PMC3663069/
- 67ncbi.nlm.nih.gov/pmc/articles/PMC7052051/
- 70ncbi.nlm.nih.gov/pmc/articles/PMC5636284/
- 71ncbi.nlm.nih.gov/pmc/articles/PMC4482415/
- 72ncbi.nlm.nih.gov/pmc/articles/PMC3450946/
- 73ncbi.nlm.nih.gov/pmc/articles/PMC4891707/
- 76ncbi.nlm.nih.gov/books/NBK560283/
- 77ncbi.nlm.nih.gov/books/NBK562276/
- 80ncbi.nlm.nih.gov/pmc/articles/PMC5077869/
- 81ncbi.nlm.nih.gov/pmc/articles/PMC3322880/
- 82ncbi.nlm.nih.gov/pmc/articles/PMC7072051/
- 106ncbi.nlm.nih.gov/pmc/articles/PMC6071412/
- 116ncbi.nlm.nih.gov/books/NBK279041/
- 122ncbi.nlm.nih.gov/pmc/articles/PMC4710614/
- 37sciencedirect.com/science/article/pii/S0090825816303217
- 46sciencedirect.com/science/article/pii/S1472648318300748
- 48pubmed.ncbi.nlm.nih.gov/23772529/
- 53rcog.org.uk/globalassets/documents/guidelines/gtg/gtg_art.pdf
- 58fertstert.org/article/S0015-0282(18)32333-1/fulltext
- 59fertstert.org/article/S0015-0282(16)32925-9/fulltext
- 64fertstert.org/article/S0015-0282(14)00344-7/fulltext
- 66nejm.org/doi/full/10.1056/NEJMoa1412184
- 68cdc.gov/nchs/pressroom/2022/20220112.htm
- 74cdc.gov/art/artdata/index.html
- 75cdc.gov/art/reports/2017/national-summary.html
- 95cdc.gov/std/treatment-guidelines/default.htm
- 78aihw.gov.au/reports/australias-health/infertility-and-assisted-reproductive-treatment
- 79aihw.gov.au/reports-data/behaviours-melanoma/infertility-and-assisted-reproductive-treatment
- 84legislation.gov.uk/ukpga/2008/22/part/6
- 86law.cornell.edu/wex/assisted_reproduction
- 87fda.gov/vaccines-blood-biologics/sperm-blood-and-other-tissues/reproductive-tissue-donors
- 93fda.gov/regulatory-information/search-fda-guidance-documents/human-cells-tissues-and-cellular-and-tissue-based-products-hctps
- 107fda.gov/regulatory-information/search-fda-guidance-documents/reproductive-tissue-donor-testing
- 126fda.gov/regulatory-information/search-fda-guidance-documents/human-cells-tissues-and-cellular-and-tissue-based-products-establishments
- 90riksdagen.se/en/search/?query=donor+assisted+reproduction+act
- 91laws-lois.justice.gc.ca/eng/acts/A-13.4/
- 92gesetze-im-internet.de/en-egschg/
- 100gesetze-im-internet.de/en_schutz_embryonen/
- 98acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/10/art-and-assisted-reproduction-technologies
- 101health.gov.il/English/Topics/Surrogacy/Pages/default.aspx
- 102psychiatry.org/psychiatrists/practice/clinical-practice-guidelines
- 108ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1271
- 109ecfr.gov/current/title-21/section-1271.75
- 110ecfr.gov/current/title-21/section-1271.80
- 111ecfr.gov/current/title-21/section-1271.90
- 114nice.org.uk/guidance/cg156/chapter/Recommendations
- 118sst.dk/en/english/health/legislation-and-guidelines/donor-conception
- 119stm.fi/en/donor-treatment
- 120boe.es/buscar/act.php?id=BOE-A-2006-9292
- 123who.int/publications/i/item/9789241544878
- 127health.govt.nz/our-work/life-stages/children/donor-assisted-reproduction